대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Initial Effect of SGLT2 Inhibitors on Kidney Function in Patients with IgA Nephropathy
저자	Jae Young Kim
출판정보	2026; 2026(1):
키워드	IgA nephropathy, SGLT2i inhibitor, proteinuria
초록	Objectives: Optimized supportive therapy, including maximal renin–angiotensin–aldosterone system (RAAS) inhibition, is not always adequate in patients with IgA nephropathy (IgAN). This study evaluated early effects of sodium–glucose cotransporter-2 inhibitors (SGLT2is) on kidney function in patients with IgAN receiving RAAS inhibitors. Methods: Adult patients who were newly diagnosed with IgAN during 2020–2024, with baseline estimated glomerular filtration rate (eGFR) ≥35 mL/min/1.73 m2, urine protein-tocreatinine ratio (UPCR) ≥0.8 g/g, and receiving RAAS inhibitors for ≥28 d were selected. The primary exposure was the incident use of SGLT2i. Changes in UPCR, urine albumin-tocreatinine ratio (UACR), and eGFR at 12 mo were examined using mixed-effect models for repeated measures with inverse probability of treatment weighting. Results: SGLT2i use was associated with an early eGFR decline (mean difference, −5.39 mL/min/1.73 m2; 95% confidence interval [CI], −9.51 to −1.26) but was not significantly associated with the reduction in UPCR (geometric mean ratio [GMR], 0.90; 95% CI, 0.68–1.18) or UACR (GMR, 0.94; 95% CI, 0.67–1.34) at 12 mo compared with non-users. However, subgroup and sensitivity analyses suggested a potential relationship between SGLT2i use and the reduction in proteinuria in patients with S0 lesions according to the Oxford classification and baseline systolic blood pressure ≥130 mmHg, indicating possible benefits despite the absence of consistent statistical significance across analyses. Conclusion: In this real-world IgAN cohort, although SGLT2i use was not associated with proteinuria reduction at 12 mo, differential subgroup responses suggest that antiproteinuric benefits may be greater in patients without segmental glomerulosclerosis or with elevated systolic blood pressure.
원문(PDF)	PDF 원문보기

목록

위로가기